Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Annual Report Finds Declines in Cancer Incidence and Death in US, But Wide Variation in Lung Cancer Trends - (DGNews)
    TopAbstracts in Breast Cancer 11/25/2008 - (DGNews)
    Mammogram Most Effective 12 Months After Radiation Treatment - (DGNews)
    Mammograms May Detect Some Cancers That Would Have Otherwise Regressed - (DGNews)
    Type of Breast Reconstruction Impacts Radiation Therapy Outcomes - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Mucinous Breast Carcinoma Presenting as Paget's Disease of the Nipple in a Man: A Case Report
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Older Women With Breast Cancer Respond to Treatment With Capecitabine and Vinorelbine: Presented at SABCS

      By Ed Susman

      SAN ANTONIO, TX -- December 18, 2006 -- More than three quarters of 26 evaluable women over age 60 who are diagnosed with metastatic breast cancer respond to treatment with capecitabine and vinorelbine, researchers reported here at the 29th San Antonio Breast Cancer Symposium (SABCS).

      "The promising response rate of 77% justifies further evaluation of this combination regimen," said Uwe Kohler, MD, PhD, professor of medicine, clinic for obstetrics and gynecology, University of Leipzig, Leipzig, Germany.

      "Half of all women with breast cancer are 58 years old or older," Dr. Kohler said in a poster presentation on December 17th. "In older patients, comorbidity and impaired organ function limit the use of taxane- or anthracycline-containing regimens. However, undertreatment in elderly patients results in poorer survival."

      In the pilot study, Dr. Kohler enrolled 30 women with a median age of 68, aiming to continue to enroll up to 77 women if the initial results showed at least a 46% response rate.

      The researchers treated these women with capecitabine 1000 mg/m2 daily on days 1 through 14, in addition to vinorelbine 25 mg/m2 on days 1 and 8, on a 21-day cycle. The treatment continued until best response, disease progression, or unacceptable toxicity occurred.

      Of the 26 evaluable patients, 3 achieved a complete response and 17 achieved a partial response; 1 patient achieved disease stabilization.

      Although the regimen contained a high dose of capecitabine, it appears to have been well tolerated, Dr. Kohler said. He said there were no cases of grade 3 hand-foot syndrome and an 8% rate of grade 3/4 diarrhea.

      "These preliminary results indicate that this combination regimen of capecitabine and vinorelbine is highly active and well tolerated as first-line therapy in patients over age 60," he said.

      Dr. Kohler presented the findings on behalf of the Northeast German Society for Gynecologic Oncology (NOGGO) breast cancer study group.


      [Presentation title: Capecitabine (C) and Vinorelbine (V) in Elderly Patients (pts.) With Metastatic Breast Cancer (MBC) as 1st Line Treatment: a Prospective Multicentre Phase II Study of the NOGGO Breast Cancer Study Group. Abstract 6089]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send